Chronic kidney disease (CKD) is common among HIV-infected individuals but serum creatinine is insensitive for detecting kidney damage at early stages. We hypothesized that HIV infection would be associated with elevations in subclinical markers of kidney injury and fibrosis in a contemporary cohort of men.
Methods
In this cross-sectional study, we measured urine levels of interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), pro-collagen type III N-terminal pro-peptide (PIIINP) and albumin-creatinine ratio (ACR) in 813 HIV-infected and 331 uninfected men enrolled in the Multi-center AIDS Cohort Study.
Results
Median eGFR was 95 ml/min/1.73 m2 among African-Americans (n=376) and 87 ml/min/1.73 m2 among Caucasians (n=768). Among HIV-infected men, the median CD4 lymphocyte count was 572 cells/mm3 and 76% of men had undetectable HIV RNA levels. After multivariable adjustment for traditional CKD risk factors including eGFR, HIV infection was associated with 52% higher urine IL-18 (95% CI, 33%, 73%), 44% higher KIM-1 (27%, 64%), 30% higher PIIINP (15%, 47%) and 84% higher ACR (54%, 120%), with similar effect sizes among African-Americans and Caucasians (P>0.2 for tests of interaction by race). These associations remained statistically significant in analyses that excluded persons with detectable HIV RNA levels and in models that adjusted for cumulative exposure to tenofovir disoproxil fumarate.
Conclusions
Compared with uninfected men, HIV-infected men had more extensive glomerular and tubulointerstitial damage, as assessed by urine biomarkers. Future studies should evaluate whether combinations of biomarkers can be used to monitor stages of kidney injury and to predict CKD risk in HIV-infected individuals.
References
1.
WyattC.M., WinstonJ.A., MalvestuttoC.D.Chronic kidney disease in HIV infection: an urban epidemic.AIDS2007; 21: 2101–2103.
2.
RaoT.K., FilipponeE.J., NicastriA.D.Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome.N Engl J Med1984; 310: 669–673.
3.
CantorE.S., KimmelP.L., BoschJ P.Effect of race on expression of acquired immunodeficiency syndrome-associated nephropathy.Arch Intern Med1991; 151: 125–128.
4.
LucasG.M., EustaceJ.A., SozioS., MentariE.K., AppiahK.A., MooreR.D.Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.AIDS2004; 18: 541–546.
5.
SzczechL.A., GuptaS.K., HabashR.The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.Kidney Int2004; 66: 1145–1152.
6.
ChoiA.I., RodriguezR.A., BacchettiP., BertenthalD., VolberdingP.A., O'HareA.M.The impact of HIV on chronic kidney disease outcomes.Kidney Int2007; 72: 1380–1387.
7.
LucasG.M., LauB., AttaM.G., FineD.M., KerulyJ., MooreR.D.Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races.J Infect Dis2008; 197: 1548–1557.
8.
De WitS., SabinC.A., WeberR.Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.Diabetes Care2008; 31: 1224–1229.
9.
ScherzerR., EstrellaM., LiY.Association of tenofovir exposure with kidney disease risk in HIV infection.AIDS2012; 26: 867–875.
10.
TsuiJ., VittinghoffE., AnastosK.Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study.Am J Kidney Dis2009; 54: 43–50.
11.
WyattC.M., MalvestuttoC., CocaS.G., KlotmanP.E., ParikhC.R.The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.AIDS2008; 22: 1799–1807.
12.
WyattC.M., MorgelloS., Katz-MalamedR.The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy.Kidney Int2009; 75: 428–434.
13.
ShlipakM.G., ScherzerR., AbrahamA.Urinary markers of kidney injury and kidney function decline in HIV-infected women.J Acquir Immune Defic Syndr2012; 61: 565–573.
14.
PeraltaC., ScherzerR., GrunfeldC.Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women's Interagency HIV Study (WIHS).HIV Med2014; 15: 291–300.
15.
JotwaniV., ScherzerR., AbrahamA.Does HIV infection promote early kidney injury in women?Antivir Ther2014; 19: 79–87.
16.
BarkanS.E., MelnickS.L., Preston-MartinS.The Women's Interagency HIV Study. WIHS Collaborative Study Group.Epidemiology1998; 9: 117–125.
17.
HerlitzL.C., MohanS., StokesM.B., RadhakrishnanJ., D'AgatiV.D., MarkowitzG.S.Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney Int2010; 78: 1171–1177.
HallA.M., HendryB.M., NitschD., ConnollyJ.O.Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.Am J Kidney Dis2011; 57: 773–780.
20.
JotwaniV., LiY., GrunfeldC., ChoiA.I., ShlipakM.Risk factors for end-stage renal disease in HIV-infected individuals: traditional and HIV-related factors.AJKD2012; 59: 628–635.
21.
KaslowR.A., OstrowD.G., DetelsR., PhairJ.P., PolkB.F., RinaldoC.R.Jr.. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.Am J Epidemiol1987; 126: 310–318.
22.
ChaturvediS., FarmerT., KapkeG.F.Assay validation for KIM-1: human urinary renal dysfunction biomarker.Int J Biol Sci2009; 5: 128–134.
23.
CastroK.G.W.J., SlutskerL.1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults: Center for Disease Control and Prevention1992.
24.
LeveyA.S., StevensL.A., SchmidC.H.A new equation to estimate glomerular filtration rate.Ann Intern Med2009; 150: 604–612.
25.
GilksW.R., RichardsonS., SpiegehalterD.J.Markov chain Monte Carlo in practice.London: Chapman & Hall; 1996.
26.
HeritierS., CantoniE., CoptS., Victoria-FeserM P.Robust methods in Biostatistics Vol 825: John Wiley & Sons; 2009.
27.
ZouG.A modified poisson regression approach to prospective studies with binary data.Am J Epidemiol2004; 159: 702–706.
28.
FlandreP., PuglieseP., CuzinL.Risk factors of chronic kidney disease in HIV-infected patients.Clin J Am Soc Nephrol2011; 6: 1700–1707.
29.
JotwaniV., ScherzerR., EstrellaM.M.Cumulative tenofovir disoproxil fumarate exposure is associated with biomarkers of tubular injury and fibrosis in HIV-infected men.J Acquir Immune Defic Syndr2016; 73: 177–181.
30.
HoetingJ.M.D., RafteryA., VolinskyC.Bayesian model averaging: a tutorial.Stat Sci1999; 14: 382–401.
31.
ParikhC.R., JaniA., MelnikovV.Y., FaubelS., EdelsteinC.L.Urinary interleukin-18 is a marker of human acute tubular necrosis.Am J Kidney Dis2004; 43: 405–414.
32.
HanW.K., BaillyV., AbichandaniR., ThadhaniR., BonventreJ V.Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.Kidney Int2002; 62: 237–244.
33.
SoylemezogluO., WildG., DalleyA.J.Urinary and serum type III collagen: markers of renal fibrosis.Nephrol Dial Transplant1997; 12: 1883–1889.
34.
GhoulB.E., SqualliT., ServaisA.Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist.Clin J Am Soc Nephrol2010; 5: 205–210.
35.
TeppoA.M., TornrothT., HonkanenE., Gronhagen-RiskaC.Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients.Transplantation2003; 75: 2113–2119.
36.
IxJ.H., BiggsM.L., MukamalK.Urine collagen fragments and CKD progression-The Cardiovascular Health Study.J Am Soc Nephrol2015; 26: 2494–2503.
37.
BruggemanL.A., RossM.D., TanjiN.Renal epithelium is a previously unrecognized site of HIV-1 infection.J Am Soc Nephrol2000; 11: 2079–2087.
38.
WinstonJ.A., BruggemanL.A., RossM.D.Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.N Engl J Med2001; 344: 1979–1984.
39.
RossM.J., BruggemanL.A., WilsonP.D., KlotmanP.E.Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy.J Am Soc Nephrol2001; 12: 2645–2651.
40.
BruggemanL.A., DikmanS., MengC., QuagginS.E., CoffmanT.M., KlotmanP.E.Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.J Clin Invest1997; 100: 84–92.
FischerM.J., WyattC.M., GordonK.Hepatitis C and the risk of kidney disease and mortality in veterans with HIV.J Acquir Immune Defic Syndr2010; 53: 222–226.
44.
GenoveseG., FriedmanD.J., RossM.D.Association of trypanolytic ApoL1 variants with kidney disease in African Americans.Science2010; 329: 841–845.
45.
TzurS., RossetS., ShemerR.Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.Hum Genet2010; 128: 345–350.
46.
PeraltaC.A., Bibbins-DomingoK., VittinghoffE.APOL1 genotype and race differences in incident albuminuria and renal function decline.J Am Soc Nephrol2016; 27: 887–893.
47.
JotwaniV., ShlipakM.G., ScherzerR.APOL1 genotype and glomerular and tubular kidney injury in women with HIV.Am J Kidney Dis2015; 65: 889–898.
